Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Irene M. Ghobrial"'
Autor:
Edie Weller, Kaitlen Reyes, James J. Vredenburgh, Adam Boruchov, Kimberly Noonan, Paul G. Richardson, Rachid Baz, Jacob P. Laubach, Abdel Kareem Azab, Houry Leblebjian, Robert L. Schlossman, Irene M. Ghobrial, Frank G. Basile, Pamela A. Crilley, Kenneth C. Anderson, Patrick Henrick, Michael Constantine, Stacey Chuma, Nikhil C. Munshi, Kenneth H. Shain, Kalvis Hornburg, Claudia E. Paba-Prada, Philippe Armand, Diane Warren, Yuji Mishima, Lorenzo Trippa, Chia Jen Liu, Oksana Zavidij
Publikováno v:
American Journal of Hematology. 94:1244-1253
We tested the hypothesis that using CXCR4 inhibition to target the interaction between the tumor cells and the microenvironment leads to sensitization of the tumor cells to apoptosis. Eligibility criteria included multiple myeloma (MM) patients with
Autor:
Youngil Koh, Lucie Lepine, Miles Prince, Valdas Peceliunas, Sevgi Kalayoglu Besisik, Irene M. Ghobrial, Codina Oprea, Emil Hermansen, Javier de la Rubia, Vania Hungria, Hang Quach, Paula Rodriguez-Otero, Maria-Victoria Mateos, Jin Seok Kim, Christine Devisme, Joaquin Martinez-Lopez, Sandrine Macé, Gurdeep Parmar, Xavier Leleu, Fredrik Schjesvold, Franck Dubin
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S109-S110
Background: High-risk smoldering multiple myeloma (HR-SMM) is associated with a greater risk of progression to symptomatic disease, suggesting the need for early, efficacious therapeutic interventions to improve outcomes. The ongoing, randomized Phas
Autor:
Ofer Shpilberg, Irene M. Ghobrial, Moshe Mittelman, Ashraf Badros, Ivan Spicka, Arnon Nagler, Kenneth C. Anderson, Richard Leblanc, Jacob P. Laubach, Kihyun Kim, Teru Hideshima, Peter Sportelli, Paul Blake, Paul G. Richardson, Moshe E. Gatt, Merav Leiba, Sung-Soo Yoon, Michael Chen, Kathleen Colson, Roman Hájek, Hakan Kaya, Joaquin Martinez-Lopez, Parameswaran Hari, Dina Ben-Yehuda
Publikováno v:
EJHaem. 1(1)
Perifosine, an investigational, oral, synthetic alkylphospholipid, inhibits signal transduction pathways of relevance in multiple myeloma (MM) including PI3K/Akt. Perifosine demonstrated anti-MM activity in preclinical studies and encouraging early-p
Autor:
Lorenzo Trippa, Jacob P. Laubach, Paul G. Richardson, Elizabeth O'Donnell, Kathleen J. Lively, Robert L. Schlossman, Tianqi Chen, Irene M. Ghobrial, Andrew Yee, Philip M. Wade, Carol Ann Huff, Frank G. Basile, Nikhil C. Munshi, Jill N. Burke, Claudia E. Paba-Prada, Kenneth C. Anderson, Hannah Lyons, Cynthia C. Harrington, Noopur Raje
Publikováno v:
British Journal of Haematology. 182:222-230
We sought a regimen that incorporates optimal novel agents and balances efficacy with toxicity in transplant-ineligible multiple myeloma (MM) patients. Our study evaluated modified lenalidomide-bortezomib-dexamethasone (RVD lite) in this population a
Autor:
Kelsey Tague, Alexandra Savell, Alexandra Distaso, Andrew Kin, Irene M. Ghobrial, Jeffrey A. Zonder, Andrew Yee, Jacalyn Rosenblatt, Veronica Romines, Meredith Bertoni, Julia Prescott, Omar Nadeem, Robert A. Redd, Paul G. Richardson, Jeffrey V. Matous, Amada Metivier, Michael Z. Koontz, Clifton C. Mo, Adam S. Sperling, Jacob P. Laubach, Rebekah Medina, Houry Leblebjian
Publikováno v:
Blood. 138:1649-1649
Introduction : Daratumumab (Dara) is an anti-CD38 monoclonal antibody that is approved for use in patients with newly diagnosed and relapsed multiple myeloma (MM). We hypothesized that early therapeutic intervention with Dara in patients with high-ri
Autor:
Aric Parnes, Julia Prescott, Omar Nadeem, Catherine R. Marinac, Robert A. Redd, Alexandra Savell, Paul G. Richardson, Courtney Igne, Irene M. Ghobrial, Adam S. Sperling, Jacob P. Laubach, Houry Leblebjian
Publikováno v:
Blood. 138:1659-1659
Background: Multiple Myeloma (MM) is thought to evolve from the precursor conditions monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM), which are common premalignant disorders that progress to overt MM in a subset of i
Autor:
Omar Nadeem, Robert Redd, Laura V. Stampleman, Jeffrey V. Matous, Andrew J. Yee, Jeffrey A. Zonder, Andrew Kin, Jacalyn Rosenblatt, Mark Bustoros, MD, Julia Prescott, Alexandra Savell, Kathleen Guimond, Erin Frey, Rachel Styles, Adrienne Bielawski, Cody J Boehner, Nang Kham Su, Multiple Myeloma Research Foundation Multiple Myeloma Research Foundation, The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society, BCRP Blood Cancer Research Partnership, Adam S Sperling, Giada Bianchi, Jacob P. Laubach, Jorge J. Castillo, Nikhil C. Munshi, Kenneth C. Anderson, Paul G. Richardson, Lorenzo Trippa, Irene M. Ghobrial
Publikováno v:
Blood. 134:1898-1898
Introduction: Daratumumab (DARA) is an anti-CD38 monoclonal antibody that is approved for use in patients with newly diagnosed and relapsed multiple myeloma (MM). We hypothesized that early therapeutic intervention with DARA in patients with high-ris
Autor:
Hannah Lyons, Robert A. Redd, Robert L. Schlossman, Nikhil C. Munshi, Kenneth C. Anderson, Irene M. Ghobrial, Philip M. Wade, Kathleen J. Lively, Jacob P. Laubach, Frank G. Basile, Elizabeth O'Donnell, Paul G. Richardson, Cynthia C. Harrington, Carol Ann Huff, Andrew Yee, Claudia E. Paba-Prada, Jill N. Burke, Noopur Raje
Publikováno v:
Blood. 134:3178-3178
PURPOSE: This updated analysis examined survival outcomes after 60 months of follow-up in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) treated with the 3-drug regimen of modified lenalidomide-bortezomib-dexamethasone (R
Autor:
Dixil Francis, Amitabha Mazumder, Teru Hideshima, Irene M. Ghobrial, Nikhil C. Munshi, John Feather, Constantine S. Mitsiades, Dixie-Lee Esseltine, Laura E. Lunde, Wanling Xie, Robert Knight, Paul G. Richardson, Melissa Alsina, Sundar Jagannath, Jonathan L. Kaufman, Robert L. Schlossman, Kathleen Colson, Diane Warren, Andrzej Jakubowiak, Michelle E. Maglio, Kenneth C. Anderson, Edie Weller, Mary McKenney, Sagar Lonial, David H. Vesole, Noopur Raje
Publikováno v:
Blood. 123:1461-1469
In this prospective, multicenter, phase 2 study, 64 patients with relapsed or relapsed and refractory multiple myeloma (MM) received up to 8 21-day cycles of bortezomib 1.0 mg/m(2) (days 1, 4, 8, and 11), lenalidomide 15 mg/day (days 1-14), and dexam
Autor:
Jacalyn Rosenblatt, Hannah Baker, Peter O'Gorman, Paul G. Richardson, Jeffrey Matous, Andrew Yee, John Harran, Thomas H. Openshaw, Irene M. Ghobrial, Bhupendra Rawal, Rodrigo O. Maegawa, Jennifer Abovich, Michaela L. Tsai, Alexandra Savell, Joshua Hansen, Kathleen Fitzpatrick, Heidi Dipietro, Kristen Cummings, Jacob P. Laubach, Charles M. Farber, Giada Bianchi, Kathleen M. Scott
Publikováno v:
Blood. 132:1981-1981
Introduction: Patients (pts) with newly diagnosed multiple myeloma (MM) are commonly treated with the standard of care combination of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex), also known as RVD. A recent randomized phase 3 study f